Over 1,000,000 men with PCa are included; however, lacking or incomplete data on risk categories, comorbidities, subsequent treatments, prostate-specific antigen (PSA) levels and follow-up limit SEER’s usefulness for monitoring disease progression and mapping the disease trajectory [12]. The gene discussed is KLK3; the disease is posterior cortical atrophy.